X-ray of Pneumocystis jiroveci pneumonia There is increased white (opacity) in the lower lungs on both sides, characteristic of Pneumocystis pneumonia
Find information on thousands of medical conditions and prescription drugs.

Pneumocystis jiroveci pneumonia

Pneumocystis jiroveci pneumonia or Pneumocystis pneumonia (PCP) is a form of pneumonia caused by a yeast-like fungal microorganism called Pneumocystis jiroveci (sometimes spelled jirovecii, formerly known as Pneumocystis carinii). It is relatively rare in people with normal immune systems but common among people with AIDS. PCP can also develop in patients who are taking immunosuppressant medications (e.g., patients who have undergone solid organ transplantion) and in patients who have undergone bone marrow transplantation. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Arthritis
Arthritis
Bubonic plague
Hypokalemia
Pachydermoperiostosis
Pachygyria
Pacman syndrome
Paget's disease of bone
Paget's disease of the...
Palmoplantar Keratoderma
Pancreas divisum
Pancreatic cancer
Panhypopituitarism
Panic disorder
Panniculitis
Panophobia
Panthophobia
Papilledema
Paraganglioma
Paramyotonia congenita
Paraphilia
Paraplegia
Parapsoriasis
Parasitophobia
Parkinson's disease
Parkinson's disease
Parkinsonism
Paroxysmal nocturnal...
Patau syndrome
Patent ductus arteriosus
Pathophobia
Patterson...
Pediculosis
Pelizaeus-Merzbacher disease
Pelvic inflammatory disease
Pelvic lipomatosis
Pemphigus
Pemphigus
Pemphigus
Pendred syndrome
Periarteritis nodosa
Perinatal infections
Periodontal disease
Peripartum cardiomyopathy
Peripheral neuropathy
Peritonitis
Periventricular leukomalacia
Pernicious anemia
Perniosis
Persistent sexual arousal...
Pertussis
Pes planus
Peutz-Jeghers syndrome
Peyronie disease
Pfeiffer syndrome
Pharmacophobia
Phenylketonuria
Pheochromocytoma
Photosensitive epilepsy
Pica (disorder)
Pickardt syndrome
Pili multigemini
Pilonidal cyst
Pinta
PIRA
Pityriasis lichenoides...
Pityriasis lichenoides et...
Pityriasis rubra pilaris
Placental abruption
Pleural effusion
Pleurisy
Pleuritis
Plummer-Vinson syndrome
Pneumoconiosis
Pneumocystis jiroveci...
Pneumocystosis
Pneumonia, eosinophilic
Pneumothorax
POEMS syndrome
Poland syndrome
Poliomyelitis
Polyarteritis nodosa
Polyarthritis
Polychondritis
Polycystic kidney disease
Polycystic ovarian syndrome
Polycythemia vera
Polydactyly
Polymyalgia rheumatica
Polymyositis
Polyostotic fibrous...
Pompe's disease
Popliteal pterygium syndrome
Porencephaly
Porphyria
Porphyria cutanea tarda
Portal hypertension
Portal vein thrombosis
Post Polio syndrome
Post-traumatic stress...
Postural hypotension
Potophobia
Poxviridae disease
Prader-Willi syndrome
Precocious puberty
Preeclampsia
Premature aging
Premenstrual dysphoric...
Presbycusis
Primary biliary cirrhosis
Primary ciliary dyskinesia
Primary hyperparathyroidism
Primary lateral sclerosis
Primary progressive aphasia
Primary pulmonary...
Primary sclerosing...
Prinzmetal's variant angina
Proconvertin deficiency,...
Proctitis
Progeria
Progressive external...
Progressive multifocal...
Progressive supranuclear...
Prostatitis
Protein S deficiency
Protein-energy malnutrition
Proteus syndrome
Prune belly syndrome
Pseudocholinesterase...
Pseudogout
Pseudohermaphroditism
Pseudohypoparathyroidism
Pseudomyxoma peritonei
Pseudotumor cerebri
Pseudovaginal...
Pseudoxanthoma elasticum
Psittacosis
Psoriasis
Psychogenic polydipsia
Psychophysiologic Disorders
Pterygium
Ptosis
Pubic lice
Puerperal fever
Pulmonary alveolar...
Pulmonary hypertension
Pulmonary sequestration
Pulmonary valve stenosis
Pulmonic stenosis
Pure red cell aplasia
Purpura
Purpura, Schoenlein-Henoch
Purpura, thrombotic...
Pyelonephritis
Pyoderma gangrenosum
Pyomyositis
Pyrexiophobia
Pyrophobia
Pyropoikilocytosis
Pyrosis
Pyruvate kinase deficiency
Uveitis
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Symptoms

Symptoms of PCP include high fever, non-productive cough, shortness of breath (especially on exertion), weight loss and night sweats. There is usually not a large amount of sputum with PCP unless the patient has an additional bacterial infection. The fungus can invade other visceral organs, such as the liver, spleen and kidney, but only in a minority of cases.

Diagnosis

The clinical diagnosis can be confirmed by the characteristic appearance of the chest x-ray which shows widespread pulmonary infiltrates, and an arterial oxygen level (pO2) strikingly lower than would be expected from symptoms. The diagnosis can be definitively confirmed by pathologic identification of the causative organism in induced sputum or bronchial washings obtained by bronchoscopy with coloration by toluidine blue or immunofluorescence assay.

PCP and AIDS

Because PCP rarely occurs without AIDS, it can be one of the first clues to a new AIDS diagnosis, though it does not generally occur unless the CD4 count is less than 200/mm³. An unusual rise in PCP cases in North America, noticed when physicians began requesting large quantities of the rarely used antibiotic pentamidine, was the first clue to the existence of AIDS in the early 1980s.

Prior to the development of more effective treatments, PCP was a common and rapid cause of death in AIDS patients. Much of the incidence of PCP has been reduced by instituting a standard practice of using oral trimethoprim/sulfamethoxazole to prevent the disease in people with CD4 counts less than 200/mm³. In populations that do not have access to preventative treatment, PCP continues to be a major cause of death in AIDS.

Treatments

Antipneumocystic medication is used with concomitant steroids in order to avoid inflammation, which causes an exacerbation of symptoms about four days after treatment begins if steroids are not used. By far the most commonly used medication is a combination of trimethoprim and sulfamethoxazole (co-trimoxazole, with the tradenames Bactrim, Septrin, or Septra), but some patients are unable to tolerate this treatment due to allergies. Other medications that are used, alone or in combination, include pentamidine, trimetrexate, dapsone, atovaquone, primaquine, and clindamycin. Treatment is usually for a period of about 21 days.

Nomenclature

The name P. jiroveci, to distinguish the organism found in humans from variants of Pneumocystis found in other animals, was first proposed in 1976, in honor of Otto Jirovec, who described Pneumocystis pneumonia in humans in 1952. After DNA analysis showed significant differences in the human variant, the proposal was made again in 1999 and has come into common use; P. carinii still describes the species found in rats. The International Code of Botanical Nomenclature would normally require the name to be spelled jirovecii rather than jiroveci; both spellings are currently in use.

Read more at Wikipedia.org


[List your site here Free!]


Noninvasive method for monitoring Pneumocystis carinii pneumonia - Dispatches
From Emerging Infectious Diseases, 12/1/03 by Michael J. Linke

The progression of Pneumocystis carinii pneumonia was temporally monitored and quantified by real-time polymerase chain reaction of P. cannii-specific DNA in oral swabs and lung homogenates from infected rats. DNA levels correlated with the number of P. carinii organisms in the rats' lungs, as enumerated by microscopic methods. This report is the first of a noninvasive, antemortem method that can be used to monitor infection in a host over time.

**********

Pneumocystis pneumonia remains a leading opportunistic infection associated with AIDS patients, even in the era of highly active antiretroviral therapy (1). In developing countries, the incidence of infection has increased dramatically, with mortality rates ranging from 20% to 80% (2). An important limitation in its clinical management has been the inability to evaluate therapeutic response or to temporally measure the organism numbers because of the absence of an in vitro culture system. Our laboratory recently showed that the presence of Pneumocystis carinii-specific amplicons obtained from swabs of the oral cavities of nonimmunocompromised adult rats (Rattus norvegicus) was predictive of the development of P carinii pneumonia after corticosteroid-induced immunosuppression (3). In the present study, we applied the oral swab technique in combination with quantification of organism-specific DNA using real-time polymerase chain reaction (PCR) to monitor the progression of infection in the rat model.

The Study

Thirty-two male Long Evans rats (140-160 g) known to harbor P. carinii were obtained from Room 004 at the Cincinnati Veterinary Medical Unit (4). All rats produced P. carinii amplicons from initial oral swab samples taken before immunosuppression. After sampling, 8 of the 32 rats were euthanized and their lungs were removed and processed as described below. The remaining 24 rats were removed from the room and individually caged under barrier conditions, as described previously (3), to prevent transmission of infection that might occur between cage mates or from the environment. Barrier conditions consisted of the following: microisolator tops for each shoebox cage, which was then housed within a BioBubble (The Colorado Clean Room Company, Fort Collins, CO); autoclaved water, into which a sterile solution of cephadrine Velosef; E.R. Squibb and Sons, Inc., Princeton, NJ) was injected for a final concentration of 0.200 mg/mL; autoclaved cages, bedding, and tops; and irradiated Lab Chow (Tekmar Irradiated Lab Chow, Harlan Industries, Indianapolis, IN). To provoke P. carinii pneumonia. 4 mg/kg of methylprednisolone acetate (Depo Medrol; The Upjohn Co., Kalamazoo, MI) was administered to the rats weekly for 10 weeks. At 4 and 7 weeks, swab samples were obtained from groups of eight rats; the rats were then euthanized. Their lungs were removed for quantification by microscopic enumeration of organism nuclei expressed as log nuclei/mL (5) and real-time PCR analysis under aseptic conditions. Six rats survived the 10 weeks of immunosuppression and were processed in an identical manner.

DNA was extracted from the oral swabs (OS) and lung homogenate (LH), as previously described (4). LH DNA was evaluated by spectrophotometric analysis at 260 and 280 nm. RC primers directed to a region of the mitochondrial large subunit rRNA (mtLSU) were used for amplification of P. carinii specific DNA (6).

Real-time PCR was performed and results were analyzed on the iCycler iQ Real-Time PCR Detection System (BioRad Laboratories, Hercules, CA) under conditions of rapid melting at 95[degrees]C, annealing for 5 s at 55[degrees]C, and collection at 76[degrees]C for 10 s with 40 cycles of amplification. Five microliters of a 1/5 dilution of OS DNA or 2.5 ng of LH DNA were used in the reactions. Taq DNA (1.25 U) polymerase (Promega, Madison, Wl) was used in the real-time PCR with a concentration of 2.5 mM Mg[Cl.sub.2] in 25-[micro]L reactions. To monitor the accumulation of the products, 0.4 [micro]L of 1/1,000 dilution of concentrated SYBR Green (Molecular Probes, Eugene, OR) was included in the reactions. All reactions were performed in triplicate. The mtLSU product was cloned into the TOPO-TA PCR cloning vector (InVitrogen, Carlsbad CA) (mtLSU-T-TA), quantified by spectrophotometry, and used to generate a standard curve. The cloned PCR product, ranging from 0.0005 pg to 0.5 pg per reaction, was used as a template; the threshold cycles ([C.sub.T]S) of these reactions were then plotted against the log amount of plasmid per reaction in picograms.

P. carinii DNA in the LH and OS samples was quantified by linear regression analysis of the [C.sub.T]S relative to the standard curve (3). The concentration of P. carinii DNA in the LH and OS samples, determined from the standard curve in picograms, was converted to copies per milliliter by multiplying by the dilution factor based on the original concentration of DNA. The LH copies were log transformed and expressed as log copies per milliliter. The specificity of the reactions was verified by analysis of the product-melting curves and by gel electrophoresis. All products were of the expected size (137 bp) and produced a single peak with a [T.sub.m] of approximately 78[degrees]C.

Microscopic enumeration of nuclei of the lung homogenates was compared to real-time PCR lung homogenate results by using Tukey-Kramer Multiple Comparisons post-test to assess significance (InStat version 3; GraphPad Software, Inc., San Diego, CA). Pre- and postimrnunosuppression OS samples were analyzed with the Mann-Whitney test (InStat v. 3). Spearman Rank Correlation was used to evaluate the correlation between microscopic enumeration and the real-time PCR output (Instat v.3).

To ensure accurate and reproducible results, the efficiency of the real-time PCR with the RC primer set was evaluated for each type of sample used in this study: mtLSU/T-TA, LH DNA, and OS DNA (Table 1). The exponential amplification and efficiency of the reactions were determined by evaluating the slope of the curve generated by plotting the log of known concentrations of template DNA vs. their [C.sub.T]s (7). The RC primer set demonstrated acceptable levels of exponential amplification and efficiency with all three templates.

The organism numbers in lung tissue, quantified by microscopic enumeration, increased from log 4.69 after 4 weeks of immunosuppression to log 9.35 after 10 weeks of immunosuppression (Figure, A.). No organisms were detected in the lungs of the eight rats euthanized before the study began (level of sensitivity = ~10,000 nuclei per lung). The amount of P. carinii--specific DNA quantified by real-time PCR in the LH samples increased substantially from 0 to 7 weeks, with similar levels after 7 and 10 weeks of immunosuppression (Figure, B). Only one of eight rats cuthanized at the initiation of the experiment produced quantifiable copies of P. carinii-specific DNA, with a level similar to those after 4 weeks of immunosuppression (data not shown). In every case, the postimmunosuppression OS taken from the rats at 4, 7, and 10 weeks had significantly more P. carinii--specific DNA than the preimmunosuppression OS taken at the initiation of the study (Figure, C). The amount of P. carinii--specific DNA in the OS samples also increased over time (Figure, C). No significant correlation was found between the amount of P. carinii DNA detected in the preimmunosuppression OS samples and the amount in the postimmunosuppression OS samples, the lung homogenates, or nuclei number, suggesting that the rats had equivalent but low levels of organisms at the initiation of the study.

[FIGURE OMITTED]

To determine the relationship between quantitation of P. carinii by real-time PCR and by microscopic enumeration, results were analyzed by Spearman rank correlation (Table 2). A significant correlation was found between both the amount of P. carinii DNA detected in the postimmunosuppression OS samples and in the LH versus the number of P carinii nuclei. A significant correlation was also detected between the real-time PCR quantitation of P carinii DNA in the OS and the LH.

Conclusions

The combination of antemortem oral swab sampling and real-time PCR amplification and quantification reported here should be useful for the study of the Pneumocystis infections in other experimental models and provides a rationale for similar studies to be conducted in the clinical setting. Real-time PCR previously has been shown to be useful for quantitation of the level of infection in the lungs of infected rats and mice, but the studies were performed on postmortem samples or purified organisms (8,9) P. jiroveci DNA levels from oral washes, induced sputa, and bronchoalveolar lavage fluids from humans have been quantified by using various real-time PCR techniques (10-13) as well, but the findings were used for diagnosis, detection, or quantification and did not obtain samples from individual hosts over time. In our study, the levels of P. carinii DNA in the oral cavities of the rats were measured temporally and shown to correlate with the numbers of organisms in the lungs, establishing the oral swab real-time PCR technique as a surrogate means of following the progress of the infection. Successful application of this method to the human infection would enhance epidemiologic studies, permit sensitive and rapid assessment of therapeutic response, and allow basic biologic questions of carriage length and potential reservoirs to be addressed.

These studies were supported by a grant from the National Institutes of Health: RO1 A129839-10 awarded to MTC.

References

(1.) Jones JL, Hanson DL, Dworkin, MS, Alderton DL, Fleming PL, Kaplan, JE, et al. Surveillance for AIDS-defining opportunistic illnesses 1992-1997. MMWR CDC Surveill Summ 1999;48:1-22.

(2.) Fisk DT, Meshnick S, Kazanjian PH. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis 2003;36:70-8.

(3.) Icenhour CR, Rebholz SL, Collins MS, Cushion MT. Widespread occurrence of Pneumocystis carinii in commercial rat colonies detected using targeted PCR and oral swabs. J Clin Microbiol 2001;39:3437-41.

(4.) Icenhour CR, Rebholz SL, Collins MS, Cushion MT. Early acquisition of Pneumocystis carinii in neonatal rats as evidenced by PCR and oral swabs. Eukaryot Cell 2002;1:414-9.

(5.) Cushion MT, Ruffolo JJ, Linke MJ, Walzer PD. Pneumocystis carinii: growth variables and estimates in the A549 and WI-38 VA13 human cell lines. Exp Parasitol 1985;60:43-54.

(6.) Palmer RJ, Cushion MT, Wakefield AE. Discrimination of rat-derived Pneumocystis cartnii f. sp. carinii and Pneumocystis carinii f. sp. ratti using the polymerase chain reaction. Mol Cell Probes 1999;13:147-55.

(7.) Stahlberg A, Aman P, Ridell B, Mostad P, Kubista M. Quantitative real-time PCR method for detection of [beta]-lymphocyte monoclonality by comparison of kappa and lambda immunoglobulin light chain expression. Clin Chem 2003;49:51-9.

(8.) Zheng M, Shellito JE, Marrero L, Zhong Q, Julian S, Ye P, et al. CD4+ T ceil-independent vaccination against Pneumocystis carinii in mice. J Clin Invest 2001;108:1469-74.

(9.) Larsen HH, Kovacs JA, Stock F, Vestereng VH, Lundgren B, Fischer SH, et al. Development of a rapid real-time PCR assay for quantitation of Pneumocystis carinii f. sp. carinii. J Clin Microbiol 2002;40:2989-93.

(10.) Helweg-Larsen J, Jensen JS, Benfield T, Svendsen UG, Lundgren JD, Lundgren B. Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol 1998;36:2068-72.

(11.) Helweg-Larsen J, Jensen JS, Lundgren B. Non-invasive diagnosis of Pneumocystis carinii pneumonia by PCR on oral washes. Lancet 1997;350:1363.

(12.) Palladino S, Kay I, Fonte R, Flexman J. Use of real-time PCR and the LightCycler system for the rapid detection of Pneumocystis carinii in respiratory specimens. Diagn Microbiol Infect Dis 2001;39:233-6.

(13.) Helweg-Larsen J, Masur II, Kovacs JA, Gill VJ, Silcott VA, Kogulan P, et al. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol 2002;40:490-4.

Michael J. Linke,* Sandy Rebholz, ([dagger]) Margaret Collins, ([dagger]) Reiko Tanaka, ([dagger]) and Melanie T. Cushion * ([dagger])

* Veterans Affairs Medical Center, Cincinnati, Ohio, USA; and ([dagger]) University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

Dr. Linke is a research microbiologist at the Veterans Affairs Medical Center in Cincinnati, Ohio. His major research interest is the role of the innate immune response in the prevention and clearance of Pneumocystis infection.

Address for correspondence: Melanie T. Cushion, Department of Internal Medicine. Division of infections Diseases, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0560, USA: tax: 513-475-6415; email: Melanie.Cushion@med.va.gov

COPYRIGHT 2003 U.S. National Center for Infectious Diseases
COPYRIGHT 2004 Gale Group

Return to Pneumocystis jiroveci pneumonia
Home Contact Resources Exchange Links ebay